2019-02866. Importer of Controlled Substances Registration

ACTION:

Notice of registration.

SUMMARY:

The registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as importers of schedule I or schedule II controlled substances.

SUPPLEMENTARY INFORMATION:

The companies listed below applied to be registered as importers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for these notices.

Company	FR docket	Published
Janssen Pharmaceuticals, Inc	83 FR 58598	November 20, 2018.
Lipomed	83 FR 58601	November 20, 2018.
Akorn, Inc	83 FR 60896	November 27, 2018.
Cambridge Isotope Laboratories	83 FR 60897	November 27, 2018.
GE Healthcare	83 FR 60899	November 27, 2018.
Fisher Clinical Services, Inc	83 FR 60900	November 27, 2018.

The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each of the company's maintenance of effective controls against diversion by inspecting and testing each company's physical security systems, verifying each company's compliance with state and local laws, and reviewing each company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or schedule II controlled substances to the above listed companies.

Dated: January 29, 2019.

John J. Martin,

Assistant Administrator.